MLMarta Lustig

Marta Lustig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marta Lustig has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Jeanette H. W. Leusen

    Center for Translational Immunology, University Medical Center, Utrecht, The Netherlands

    2 shared publications
  • Thomas Valerius

    Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany

    2 shared publications
  • Chilam Chan

    Center for Translational Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

    1 shared publication
  • Christoph Hahn

    Division of Stem Cell Transplantation and Cellular Immunotherapies, Department of Medicine II, University Medical Center Schleswig-Holstein and Christian-Albrechts-University Kiel, Kiel, Germany

    1 shared publication
  • Christoph Hahn

    Division of Stem Cell Transplantation and Cellular Immunotherapy, Christian-Albrechts-University, 24105 Kiel, Germany

    1 shared publication
  • Felix Meiser

    Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, 64287 Darmstadt, Germany

    1 shared publication

Latest Publications

  • Open Access

    Tumor Acidosis Boosts Antibody-Driven Cytotoxic Potential of Neutrophils

    by Tosca Holtrop, Ida C. van der Peet, Ilona S. T. Hendriks, Tineke Kardol-Hoefnagel, Robin B. Schol, Marta Lustig, Kevin Budding, Jeanette H. W. Leusen, Patricia A. Olofsen, Maria Tsioumpekou

    The acidic tumor microenvironment (pH 6.3–7.1) influences immune cell function, yet its impact on antibody-mediated killing remains poorly understood. While natural killer (NK) cells lose their spontaneous tumor-killing ability in acidic conditions, the effect on IgG-mediated killing is unexplored. Neutrophils, key effector cells in IgA immunotherapy, respond to pH changes by delayed apoptosis and show impaired bacterial killing. In this study, we investigated how extracellular acidity affects immune cell function and modulates antibody-dependent cytotoxicity by neutrophils and peripheral blood mononuclear cells (PBMCs) across multiple in vitro tumor models. Contrary to expectations, acidity significantly enhanced both IgG- and IgA-mediated tumor cell killing by neutrophils, while IgG-mediated antibody-dependent cellular cytotoxicity (ADCC) by PBMCs had a varying impact. This increased neutrophil activity was accompanied by elevated IgA-driven trogocytosis, while protumor reactive oxygen species production and neutrophil extracellular trap (NET) formation were suppressed. Cytokine profiling and Western blot analysis revealed increased Leukotriene B4 (LTB4) secretion and extracellular signal-regulated kinase (Erk) signaling, supporting enhanced neutrophil recruitment and activation in acidic conditions. Our findings reveal that, unlike other immune subsets, neutrophils maintain or even boost antibody-mediated effector functions in the acidic tumor microenvironment, providing new insight into neutrophil biology in tumors and supporting further investigation of neutrophil-targeted antibody immunotherapies.

  • Open Access

    Fc-Silenced CD89 × EGFR Bispecific Antibodies Promote Neutrophil and Macrophage Antitumor Activity

    by Felix Meiser, Julia Harwardt, Christoph Hahn, Marta Lustig, Thomas Valerius, Harald Kolmar

    Background/Objectives: CD89 (FcaRI), the receptor for immunoglobulin A (IgA), is expressed on myeloid cells, including neutrophils, monocytes, and macrophages. It is known to mediate potent effector functions against tumor cells, but the clinical development of IgA-based therapeutics is hindered by manufacturing challenges and IgA’s short plasma half-life. Methods: Using yeast display, we generated EGFR × CD89 bispecific common light chain antibodies and investigated their biophysical properties, neutrophil-mediated cytotoxicity and macrophage phagocytosis in vitro. Results: CD89-targeting constructs induced potent neutrophil cytotoxicity and macrophage phagocytosis in vitro. A symmetric 2 + 2 IgG1 Fc-silenced variant showed the most consistent potency across neutrophil and macrophage effector functions. Fc silencing enhanced neutrophil ADCC and did not induce detectable neutrophil or PBMC fratricide under the conditions tested, suggesting a limited propensity for off-target immune cell killing. Conclusions: These findings support further preclinical evaluation of CD89-targeting bispecific antibodies and indicate that Fc silencing may differentially shape neutrophil- and macrophage-mediated antitumor activity.

  • Open Access

    Sialylation inhibition improves macrophage mediated tumor cell phagocytosis of breast cancer cells triggered by therapeutic antibodies of different isotypes

    by Marta Lustig, Christoph Hahn, Marie Leangen Herigstad, Jan Terje Andersen, Jeanette H. W. Leusen, Renate Burger, Thomas Valerius

    Tumor cell phagocytosis by macrophages is considered a relevant mechanism of action for many therapeutic IgG antibodies. However, tumor cells employ several mechanisms to evade immune recognition, including hypersialylation. Here, we describe how reduction of sialic acid exposure on tumor cells promotes antibody-dependent tumor cell phagocytosis (ADCP) by macrophages. Incubation with the sialyltransferase inhibitor (STi) P-3Fax-Neu5Ac reduced sialylation on two breast cancer cell lines, rendering these cells more susceptible to macrophage mediated phagocytosis by EGFR or HER2 antibodies. This was observed with not only IgG1 and IgG2 antibodies but also IgA2 variants. These results show that inhibiting sialic acid exposure triggers enhanced tumor cell phagocytosis by macrophages irrespective of the antibody isotype and the tumor target antigen. Investigating the underlying mechanisms of enhanced ADCP, we observed reduced binding of soluble sialic acid-binding immunoglobulin-like lectins (Siglec)-7 and Siglec-9 to tumor cells after sialylation inhibition. However, Fc silent blocking antibodies against Siglec-7 or Siglec-9, or their combination, only marginally improved ADCP. Our results further promote the concept of cancer hypersialylation as immune escape mechanism, which could serve as target to improve tumor immunotherapy with monoclonal antibodies.


  • Open Access

    Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9

    by Chilam Chan, Marta Lustig, J. H. Marco Jansen, Laura Garcia Villagrasa, Leon Raymakers, Lois A. Daamen, Thomas Valerius, Geert van Tetering, Jeanette H. W. Leusen

    Immunotherapy with targeted therapeutic antibodies is often ineffective in long-term responses in cancer patients due to resistance mechanisms such as overexpression of checkpoint molecules. Similar to T lymphocytes, myeloid immune cells express inhibitory checkpoint receptors that interact with ligands overexpressed on cancer cells, contributing to treatment resistance. While CD47/SIRPα-axis inhibitors in combination with IgA therapy have shown promise, complete tumor eradication remains a challenge, indicating the presence of other checkpoints. We investigated hypersialylation on the tumor cell surface as a potential myeloid checkpoint and found that hypersialylated cancer cells inhibit neutrophil-mediated tumor killing through interactions with sialic acid-binding immunoglobulin-like lectins (Siglecs). To enhance antibody-dependent cellular cytotoxicity (ADCC) using IgA as therapeutic, we explored strategies to disrupt the interaction between tumor cell sialoglycans and Siglecs expressed on neutrophils. We identified Siglec-9 as the primary inhibitory receptor, with Siglec-7 also playing a role to a lesser extent. Blocking Siglec-9 enhanced IgA-mediated ADCC by neutrophils. Concurrent expression of multiple checkpoint ligands necessitated a multi-checkpoint-blocking approach. In certain cancer cell lines, combining CD47 blockade with desialylation improved IgA-mediated ADCC, effectively overcoming resistance that remained when blocking only one checkpoint interaction. Our findings suggest that a combination of CD47 blockade and desialylation may be necessary to optimize cancer immunotherapy, considering the upregulation of checkpoint molecules by tumor cells to evade immune surveillance.